Work

Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas

FWCI: 0.15
Cites:
Cited by: 2
Related to: 10